• Jump to main navigation
  • Jump to content
U of U Health
  • Billing & Insurance
  • MyChart
Search
  • Find A U of U Health Doctor
  • All U of U Health Services
  • All U of U Health Locations
  • For All U of U Health Patients & Visitors
    • Patient Services
      • Questions About Your Bill?
      • Urgent Care
      • Where to Stay
      • Patients & Family Services
      • Clinical Trials
    • University of Utah Hospital
      • University of Utah Hospital
      • Staying at the Hospital
      • Parking & Valet
      • Looking for Another Location?
    • General Questions
      • 801-581-2668
      • Find an Interpreter
      • About U of U Health
  • Billing & Insurance
  • MyChart
  • Search

Kevin M. Watt, MD, PhD

Chief, Division of Pediatric Clinical Pharmacology

  • Clinical Information
  • Academic Information
  • Clinical Trials
  • Patient Resources
  • Videos & News
No Rating Available?
In order to provide our patients and visitors with the most accurate and useful information, we only post physician satisfaction data when a physician has received a minimum of 30 returned surveys. For this provider, we have not yet received the minimum.
0 out of 5 Patient Rating

Languages Spoken:

Dr. Kevin Watt received his medical degree and PhD from the University of North Carolina at Chapel Hill. He completed his pediatric residency, pediatric critical care fellowship, and a research fellowship at Duke University. He was a faculty member at Duke for 7 years before accepting a position in 2019 at the University of Utah. He is currently the Robert M. Ward Endowed Chair in Clinical Pharmacology and an Associate Professor of Pediatrics. He serves as the Chief of the Division of Clinical Pharmacology in the Department of Pediatrics and treats patients in the pediatric intensive care unit at Primary Children’s Hospital.

Dr. Watt’s research career spans over twenty-four years at institutions such as the Thomas J Watson Foundation, The JW Jones Ecological Research Center and the Duke Clinical Research Institute at Duke University. This research coincided with his work in the US Food and Drug Administration where his focus was appropriate dosage and labeling for prescription drugs for children.

Dr. Watt’s overarching career goals are to advance public health by optimizing drug therapy in critically ill children and to train the future generation of health care scientists. To accomplish these goals, I lead a multidisciplinary team of cross-trained scientists and staff who have expertise in critical illness physiology, advanced pharmacokinetic (PK)/ pharmacodynamic (PD) modeling, biostatistics, and clinical trial design and conduct. His NIH-funded research program uses modeling and simulation to determine optimal drug dosing in vulnerable populations (e.g., critically ill children, breastfeeding women and their infants). In addition, he has led and continues to lead, single and multi-center trials for pediatric labeling including several first-in-human and first-in-children trials. He serves in a leadership role in the NICHD-funded Collaborative Pediatric Critical Research Network and the NCATS-funded Utah Trial Innovation Center and HEAL-initiative.

Specialties

  • Pediatric Critical Care

Board Certification and Academic Information

Academic Departments Pediatrics - Associate Professor
Pharmacology and Toxicology - Adjunct Associate Professor
Academic Divisions Pediatric Clinical Pharmacology
Board Certification American Board of Clinical Pharmacology
American Board of Pediatrics (Pediatrics)
American Board of Pediatrics (Sub: Pediatric Critical Care Medicine)

Dr. Kevin Watt received his medical degree and PhD from the University of North Carolina at Chapel Hill. He completed his pediatric residency, pediatric critical care fellowship, and a research fellowship at Duke University. He was a faculty member at Duke for 7 years before accepting a position in 2019 at the University of Utah. He is currently the Robert M. Ward Endowed Chair in Clinical Pharmacology and an Associate Professor of Pediatrics. He serves as the Chief of the Division of Clinical Pharmacology in the Department of Pediatrics and treats patients in the pediatric intensive care unit at Primary Children’s Hospital.

Dr. Watt’s research career spans over twenty-four years at institutions such as the Thomas J Watson Foundation, The JW Jones Ecological Research Center and the Duke Clinical Research Institute at Duke University. This research coincided with his work in the US Food and Drug Administration where his focus was appropriate dosage and labeling for prescription drugs for children.

Dr. Watt’s overarching career goals are to advance public health by optimizing drug therapy in critically ill children and to train the future generation of health care scientists. To accomplish these goals, I lead a multidisciplinary team of cross-trained scientists and staff who have expertise in critical illness physiology, advanced pharmacokinetic (PK)/ pharmacodynamic (PD) modeling, biostatistics, and clinical trial design and conduct. His NIH-funded research program uses modeling and simulation to determine optimal drug dosing in vulnerable populations (e.g., critically ill children, breastfeeding women and their infants). In addition, he has led and continues to lead, single and multi-center trials for pediatric labeling including several first-in-human and first-in-children trials. He serves in a leadership role in the NICHD-funded Collaborative Pediatric Critical Research Network and the NCATS-funded Utah Trial Innovation Center and HEAL-initiative.

Academic Locations

Board Certification and Academic Information

Academic Departments Pediatrics - Associate Professor
Pharmacology and Toxicology - Adjunct Associate Professor
Academic Divisions Pediatric Clinical Pharmacology
Board Certification American Board of Clinical Pharmacology
American Board of Pediatrics (Pediatrics)
American Board of Pediatrics (Sub: Pediatric Critical Care Medicine)

Education History

Graduate Training University of North Carolina Eshelman School of Pharmacy
Pharmaceutical Sciences
Ph.D., 2016
Fellowship Duke Clinical Research Institute
Pediatric Clinical Research
Clinical Research Fellow, 2012
Fellowship Duke University School of Medicine
Pediatric Critical Care
Fellow, 2012
Internship/Residency Duke University School of Medicine
Pediatrics
Intern/Resident, 2009
Professional Medical University of North Carolina School of Medicine
Medicine
M.D., 2006
Undergraduate University of the South
Natural Resources
B.S., 1994

Selected Publications - Journal Articles

Journal Article

  1. Gerhart JG, Carreo FO, Ford JL, Edginton AN, Perrin EM, Watt KM, Muller WJ, Atz AM, Al-Uzri A, Delmore P, Gonzalez D, BestPharmaceuticals for Children Act-Pediatric Trials Network Steering Committee (2022). Use of physiologically-based pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesity. CPT Pharmacometrics Syst Pharmacol, 11(6), 778-791.
  2. Stitt G, Dubinsky S, Edginton A, Huang YV, Zuppa AF, Watt K, Downes K (2022). Antimicrobial Dosing Recommendations in Pediatric Continuous Renal Replacement Therapy: A Critical Appraisal of Current Evidence. Front Pediatr, 10, 889958.
  3. Job KM, Dallmann A, Parry S, Saade G, Haas DM, Hughes B, Berens P, Chen JY, Fu C, Humphrey K, Hornik C, Balevic S, Zimmerman K, Watt K (2022). Development of a Generic Physiologically-Based Pharmacokinetic Model for Lactation and Prediction of Maternal and Infant Exposure to Ondansetron via Breast Milk. Clin Pharmacol Ther.
  4. Baserga M, DuPont TL, Ostrander B, Minton S, Sheffield M, Balch AH, Bahr TM, Watt KM (2021). Dexmedetomidine Use in Infants Undergoing Cooling Due to Neonatal Encephalopathy (DICE Trial): A Randomized Controlled Trial: Background, Aims and Study Protocol. Front Pain Res (Lausanne), 2, 770511.
  5. Dubinsky S, Watt K, Saleeb S, Ahmed B, Carter C, Yeung CHT, Edginton A (2021). Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.
  6. Imburgia CE, Rower JE, Green DJ, Mcknite AM, Kelley WE, Reilly CA, Watt KM (2021). Remdesivir and GS-441524 Extraction by Ex Vivo Extracorporeal Life Support Circuits. ASAIO J.
  7. Tan WW, Watt KM, Boakye-Agyeman F, Cohen-Wolkowiez M, Mok YH, Yung CF, Chan YH (2021). Optimal Dosing of Meropenem in a Small Cohort of Critically Ill Children Receiving Continuous Renal Replacement Therapy. J Clin Pharmacol, 61(6), 744-754.
  8. Chambers CD, Krishnan JA, Alba L, Albano JD, Bryant AS, Carver M, Cohen LS, Gorodetsky E, Hernandez-Diaz S, Honein MA, Jones BL, Murray RK, Namazy JA, Sahin L, Spong CY, Vasisht KP, Watt K, Wurst KE, Yao L, Schatz M (2021). The safety of asthma medications during pregnancy and lactation: Clinical management and research priorities. J Allergy Clin Immunol, 147(6), 2009-2020.
  9. Yellepeddi VK, Parashar K, Dean SM, Watt KM, Constance JE, Baker OJ (2020). Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically-Based Pharmacokinetic Modeling. Clin Transl Sci, 14(2), 683-691.
  10. McDaniel CG, Honeycutt CC, Watt KM (2020). Amiodarone Extraction by the Extracorporeal Membrane Oxygenation Circuit. J Extra Corpor Technol, 53(1), 68-74.
  11. Van Eldik LJ, Sawaki L, Bowen K, Laskowitz DT, Noveck RJ, Hauser B, Jordan L, Spears TG, Wu H, Watt K, Raja S, Roy SM, Watterson DM, Guptill JT (2020). First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers. Clin Pharmacol Drug Dev, 10(2), 131-143.
  12. Maharaj AR, Wu H, Zimmerman KO, Autmizguine J, Kalra R, Al-Uzri A, Sherwin CMT, Goldstein SL, Watt K, Erinjeri J, Payne EH, Cohen-Wolkowiez M, Hornik CP (2020). Population pharmacokinetics of olanzapine in children. Br J Clin Pharmacol, 87(2), 542-554.
  13. Yellepeddi V, Sayre C, Burrows A, Watt K, Davies S, Strauss J, Battaglia M (2020). Stability of extemporaneously compounded amiloride nasal spray. PLoS One, 15(7), e0232435.
  14. Dallefeld SH, Sherwin J, Zimmerman KO, Watt KM (2019). Dexmedetomidine extraction by the extracorporeal membrane oxygenation circuit: results from an in vitro study. Perfusion, 35(3), 209-216.
  15. Zimmerman KO, Dallefeld SH, Hornik CP, Watt KM (2020). Sedative and Analgesic Pharmacokinetics During Pediatric ECMO. J Pediatr Pharmacol Ther, 25(8), 675-688.
  16. Maharaj AR, Wu H, Zimmerman KO, Speicher DG, Sullivan JE, Watt K, Al-Uzri A, Payne EH, Erinjeri J, Lin S, Harper B, Melloni C, Hornik CP, Best Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee (2019). Dosing of Continuous Fentanyl Infusions in Obese Children: A Population Pharmacokinetic Analysis. J Clin Pharmacol.
  17. Hornik CP, Yogev R, Mourani PM, Watt KM, Sullivan JE, Atz AM, Speicher D, Al-Uzri A, Adu-Darko M, Payne EH, Gelber CE, Lin S, Harper B, Melloni C, Cohen-Wolkowiez M, Gonzalez D, Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee (2019). Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents. J Clin Pharmacol, 59(12), 1606-1619.
  18. Zimmerman KO, Wu H, Laughon M, Greenberg RG, Walczak R, Schulman SR, Smith PB, Hornik CP, Cohen-Wolkowiez M, Watt KM (2019). Dexmedetomidine Pharmacokinetics and a New Dosing Paradigm in Infants Supported With Cardiopulmonary Bypass. Anesth Analg, 129(6), 1519-1528.
  19. Gonski S, Hupp SR, Cotten CM, Clark RH, Laughon M, Watt K, Hornik CP, Kumar K, Smith PB, Greenberg RG (2019). Risk of development of treated retinopathy of prematurity in very low birth weight infants. J Perinatol, 39(11), 1562-1568.
  20. Kyler KE, Wagner J, Hosey-Cojocari C, Watt K, Shakhnovich V (2019). Drug Dose Selection in Pediatric Obesity: Available Information for the Most Commonly Prescribed Drugs to Children. Paediatr Drugs, 21(5), 357-369.
  21. Gerhart JG, Watt KM, Edginton A, Wade KC, Salerno SN, Benjamin DK Jr, Smith PB, Hornik CP, Cohen-Wolkowiez M, Duara S, Ross A, Shattuck K, Stewart DL, Neu N, Gonzalez D, Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee (2019). Physiologically-Based Pharmacokinetic Modeling of Fluconazole Using Plasma and Cerebrospinal Fluid Samples From Preterm and Term Infants. CPT Pharmacometrics Syst Pharmacol, 8(7), 500-510.
  22. Watt KM, Hornik CP, Balevic SJ, Mundakel G, Cotten CM, Harper B, Benjamin DK Jr, Anand R, Laughon M, Smith PB, Cohen-Wolkowiez M, Best Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee (2019). Pharmacokinetics of ticarcillin-clavulanate in premature infants. Br J Clin Pharmacol, 85(5), 1021-1027.
  23. Watt KM, Cohen-Wolkowiez M, Barrett JS, Sevestre M, Zhao P, Brouwer KLR, Edginton AN (2018). Physiologically Based Pharmacokinetic Approach to Determine Dosing on Extracorporeal Life Support: Fluconazole in Children on ECMO. CPT Pharmacometrics Syst Pharmacol, 7(10), 629-637.
  24. Sherwin J, Thompson E, Hill KD, Watt K, Lodge AJ, Gonzalez D, Hornik CP (2018). Clinical pharmacology considerations for children supported with ventricular assist devices. Cardiol Young, 28(9), 1082-1090.
  25. Zimmerman KO, Wu H, Laughon M, Greenberg RG, Walczak R, Schulman SR, Smith PB, Hornik CP, Cohen-Wolkowiez M, Watt KM (2018). Dexmedetomidine Pharmacokinetics and a New Dosing Paradigm in Infants Supported With Cardiopulmonary Bypass. Anesth Analg.
  26. Watt KM, Avant D, Sherwin J, Benjamin DK, Hornik C, Benjamin DK Jr, Li JS, Smith PB (2017). Effect of renal function on antihypertensive drug safety and efficacy in children. Pediatr Nephrol, 33(1), 139-146.
  27. Salerno SN, Edginton A, Cohen-Wolkowiez M, Hornik CP, Watt KM, Jamieson BD, Gonzalez D (2017). Development of an Adult Physiologically Based Pharmacokinetic Model of Solithromycin in Plasma and Epithelial Lining Fluid. CPT Pharmacometrics Syst Pharmacol, 6(12), 814-822.
  28. Hornik CP, Wu H, Edginton AN, Watt K, Cohen-Wolkowiez M, Gonzalez D (2017). Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data. Clin Pharmacokinet, 56(11), 1343-1353.
  29. Watt KM, Cohen-Wolkowiez M, Williams DC, Bonadonna DK, Cheifetz IM, Thakker D, Benjamin DK Jr, Brouwer KLR (2017). Antifungal Extraction by the Extracorporeal Membrane Oxygenation Circuit. J Extra Corpor Technol, 49(3), 150-159.
  30. Gonzalez D, Bradley JS, Blumer J, Yogev R, Watt KM, James LP, Palazzi DL, Bhatt-Mehta V, Sullivan JE, Zhang L, Murphy J, Ussery XT, Puttagunta S, Dunne MW, Cohen-Wolkowiez M (2017). Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age. Pediatr Infect Dis J, 36(7), 645-653.
  31. Smith MJ, Gonzalez D, Goldman JL, Yogev R, Sullivan JE, Reed MD, Anand R, Martz K, Berezny K, Benjamin DK Jr, Smith PB, Cohen-Wolkowiez M, Watt K, Best Pharmaceuticals for Children ActPediatric Trials Network Steering Committee (2017). Pharmacokinetics of Clindamycin in Obese and Nonobese Children. Antimicrob Agents Chemother, 61(4).
  32. Autmizguine J, Hornik CP, Benjamin DK Jr, Brouwer KL, Hupp SR, Cohen-Wolkowiez M, Watt KM (2016). Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation. Pediatr Infect Dis J, 35(11), 1204-1210.
  33. Sherwin J, Heath T, Watt K (2016). Pharmacokinetics and Dosing of Anti-infective Drugs in Patients on Extracorporeal Membrane Oxygenation: A Review of the Current Literature. Clin Ther, 38(9), 1976-94.
  34. McMahon AW, Watt K, Wang J, Green D, Tiwari R, Burckart GJ (2016). Stratification, Hypothesis Testing, and Clinical Trial Simulation in Pediatric Drug Development. Ther Innov Regul Sci, 2016.
  35. Zimmerman KO, Hornik CP, Ku L, Watt K, Laughon MM, Bidegain M, Clark RH, Smith PB (2015). Sedatives and Analgesics Given to Infants in Neonatal Intensive Care Units at the End of Life. J Pediatr, 167(2), 299-304.e3.
  36. Kanesvaran R, Watt K, Turnbull JD, Armstrong AJ, Wolkowiez MC, George DJ (2014). A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma. Clin Genitourin Cancer, 13(4), 319-327.
  37. Watt KM, Gonzalez D, Benjamin DK Jr, Brouwer KL, Wade KC, Capparelli E, Barrett J, Cohen-Wolkowiez M (2015). Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation. Antimicrob Agents Chemother, 59(7), 3935-43.
  38. Harskamp-van Ginkel MW, Hill KD, Becker KC, Testoni D, Cohen-Wolkowiez M, Gonzalez D, Barrett JS, Benjamin DK Jr, Siegel DA, Banks P, Watt KM, Best Pharmaceuticals for Children ActPediatric Trials Network Administrative Core Committee (2015). Drug Dosing and Pharmacokinetics in Children With Obesity: A Systematic Review. JAMA Pediatr, 169(7), 678-85.
  39. Williams DC, Turi JL, Hornik CP, Bonadonna DK, Williford WL, Walczak RJ, Watt KM, Cheifetz IM (2014). Circuit oxygenator contributes to extracorporeal membrane oxygenation-induced hemolysis. ASAIO J, 61(2), 190-5.
  40. Pineda LC, Watt KM (2014). New antibiotic dosing in infants. Clin Perinatol, 42(1), 167-76, ix-x.
  41. Zhao W, Le Guellec C, Benjamin DK Jr, Hope WW, Bourgeois T, Watt KM, van den Anker JN, Matrot B, Saxen H, Hoppu K, Manzoni P, Jacqz-Aigrain E (2014). First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole. Clin Pharmacokinet, 53(11), 1005-18.
  42. Autmizguine J, Moran C, Gonzalez D, Capparelli EV, Smith PB, Grant GA, Benjamin DK Jr, Cohen-Wolkowiez M, Watt KM (2014). Vancomycin cerebrospinal fluid pharmacokinetics in children with cerebral ventricular shunt infections. Pediatr Infect Dis J, 33(10), e270-2.
  43. Gonzalez D, Melloni C, Yogev R, Poindexter BB, Mendley SR, Delmore P, Sullivan JE, Autmizguine J, Lewandowski A, Harper B, Watt KM, Lewis KC, Capparelli EV, Benjamin DK Jr, Cohen-Wolkowiez M, Best Pharmaceuticals for Children Act Pediatric Trials Network Administrative Core Committee (2014). Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents. Clin Pharmacol Ther, 96(4), 429-37.
  44. Cohen-Wolkowiez M, Watt KM, Zhou C, Bloom BT, Poindexter B, Castro L, Gao J, Capparelli EV, Benjamin DK Jr, Smith PB (2014). Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants. Antimicrob Agents Chemother, 58(5), 2856-65.
  45. Autmizguine J, Benjamin DK Jr, Smith PB, Sampson M, Ovetchkine P, Cohen-Wolkowiez M, Watt KM (2013). Pharmacokinetic studies in infants using minimal-risk study designs. Curr Clin Pharmacol, 9(4), 350-8.
  46. Autmizguine J, Watt KM, Thort Y, Kassir N, Laferrire C, Parent S, Tapiro B, Ovetchkine P (2013). Pharmacokinetics and pharmacodynamics of oral cephalexin in children with osteoarticular infections. Pediatr Infect Dis J, 32(12), 1340-4.
  47. Downey LC, Benjamin DK Jr, Clark RH, Watt KM, Hornik CP, Laughon MM, Cohen-Wolkowiez M, Smith PB (2012). Urinary tract infection concordance with positive blood and cerebrospinal fluid cultures in the neonatal intensive care unit. J Perinatol, 33(4), 302-6.
  48. Manzoni P, Benjamin DK Jr, Franco C, Rizzollo S, Stronati M, Watt K, Cohen-Wolkowiez M, Jacqz-Aigrain E (2011). Echinocandins for the nursery: an update. Curr Drug Metab, 14(2), 203-7.
  49. Watt K, Manzoni P, Cohen-Wolkowiez M, Rizzollo S, Boano E, Jacqz-Aigrain E, Benjamin DK (2011). Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole. Curr Drug Metab, 14(2), 193-202.
  50. Sampson M, Cohen-Wolkowiez M, Benjamin D Jr, Capparelli E, Watt K (2014). Pharmacokinetics of Antimicrobials in Obese Children. GaBI J, 2(2), 76-81.
  51. Cohen-Wolkowiez M, Poindexter B, Bidegain M, Weitkamp JH, Schelonka RL, Randolph DA, Ward RM, Wade K, Valencia G, Burchfield D, Arrieta A, Mehta V, Walsh M, Kantak A, Rasmussen M, Sullivan JE, Finer N, Rich W, Brozanski BS, van den Anker J, Blumer J, Laughon M, Watt KM, Kearns GL, Capparelli EV, Martz K, Berezny K, Benjamin DK Jr, Smith PB, Meropenem Study Team (2012). Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. Clin Infect Dis, 55(11), 1495-502.
  52. Tripathi N, Watt K, Benjamin DK Jr (2012). Treatment and prophylaxis of invasive candidiasis. Semin Perinatol, 36(6), 416-23.
  53. Watt KM, Benjamin DK Jr, Cheifetz IM, Moorthy G, Wade KC, Smith PB, Brouwer KL, Capparelli EV, Cohen-Wolkowiez M (2012). Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation. Pediatr Infect Dis J, 31(10), 1042-7.
  54. Cohen-Wolkowiez M, Watt KM, Hornik CP, Benjamin DK Jr, Smith PB (2012). Pharmacokinetics and tolerability of single-dose daptomycin in young infants. Pediatr Infect Dis J, 31(9), 935-7.
  55. Watt KM, Walgos J, Cheifetz IM, Turner DA (2012). Dexmedetomidine for transport of a spontaneously breathing combative child. Pediatrics, 130(3), e690-4.
  56. Watt KM, Cohen-Wolkowiez M, Ward RM, Benjamin DK Jr (2012). Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future. Pediatr Infect Dis J, 31(6), 635-7.
  57. Ascher SB, Smith PB, Watt K, Benjamin DK, Cohen-Wolkowiez M, Clark RH, Benjamin DK Jr, Moran C (2011). Antifungal therapy and outcomes in infants with invasive Candida infections. Pediatr Infect Dis J, 31(5), 439-43.
  58. Hornik CP, Fort P, Clark RH, Watt K, Benjamin DK Jr, Smith PB, Manzoni P, Jacqz-Aigrain E, Kaguelidou F, Cohen-Wolkowiez M (2012). Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units. Early Hum Dev, 88 Suppl 2, S69-74.
  59. Ascher SB, Smith PB, Clark RH, Cohen-Wolkowiez M, Li JS, Watt K, Jacqz-Aigrain E, Kaguelidou F, Manzoni P, Benjamin DK Jr (2012). Sepsis in young infants with congenital heart disease. Early Hum Dev, 88 Suppl 2, S92-7.
  60. Watt KM, Massaro MM, Smith B, Cohen-Wolkowiez M, Benjamin DK Jr, Laughon MM (2011). Pharmacokinetics of moxifloxacin in an infant with Mycoplasma hominis meningitis. Pediatr Infect Dis J, 31(2), 197-9.
  61. Watt K, Li JS, Benjamin DK Jr, Cohen-Wolkowiez M (2011). Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation. J Cardiovasc Pharmacol, 58(2), 126-32.
  62. Watt K, Benjamin DK Jr, Cohen-Wolkowiez M (2011). Pharmacokinetics of antifungal agents in children. Early Hum Dev, 87 Suppl 1, S61-5.
  63. Watt K, Waddle E, Jhaveri R (2010). Changing epidemiology of serious bacterial infections in febrile infants without localizing signs. PLoS One, 5(8), e12448.

Editorial

  1. Watt KM (2020). How to Rapidly Determine First-in-Children Dosing for COVID-19 Therapeutics. JAMA Pediatr, 174(10), e202435.

Tocilizumab or TCQ: A Study Drug for Pediatric Patients with COVID-19

Description: Keywords: Principal Investigator: Kevin Watt

Feature News

Personalized Medicine Approach for Critically Ill Children

Site Links

  • Find an Interpreter
  • About Us
  • Academics & Research
  • Billing
  • Jobs
  • Giving
  • Maps & Directions
  • Newsroom
  • Referring Providers

Helpful Links

  • Patient Rights & Responsibilities
  • Disclaimer
  • Privacy Statement
  • DNV GL Public Information Policy Statement
  • Non-Discrimination Policy
  • Surprise Billing Rights
  • Webmaster

Contact Us

University of Utah Health

50 North Medical Drive
Salt Lake City, UT 84132

801-581-2121

  • Facebook
  • Twitter
  • Youtube
  • Instagram

University of Utah

All clinical services and programs are part of University of Utah Health Hospitals and Clinics.

Copyright © 2022 University of Utah Health